
Claims


1. A compound represented by the following formula [I], or a pharmaceutically acceptable salt thereof~~, or a solvate thereof~~:




[I]

wherein

the partial structural formula:



is a group represented by any of the following formulas:



;

$R^1$ is

(1) a hydrogen atom,

(2) a $C_{1-6}$ alkyl group,

(3) a $C_{6-14}$ aryl group,

(4) a $C_{3-8}$ cycloalkyl group,

(5) a $C_{6-14}$ aryl-$C_{1-6}$ alkyl group, or

(6) a $C_{3-8}$ cycloalkyl-$C_{1-6}$ alkyl group;


$R^2$ is

(1) a hydrogen atom,


(2) a $C_{1-10}$ alkyl group,

(3) a $C_{6-14}$ aryl group optionally substituted by the same or different 1 to 5 substituents selected from the following group

2. The compound according to claim 1 wherein the partial structural formula:




is a group represented by the following formula




,

or a pharmaceutically acceptable salt thereof~~, or a solvate thereof~~.

3. The compound according to claim 1, wherein the partial structural formula:




is a group represented by the following formula




,

or a pharmaceutically acceptable salt thereof~~, or a solvate thereof~~.

4. The compound according to claim 1, wherein the partial structural formula:




is a group represented by the following formula




or a pharmaceutically acceptable salt thereof~~, or a solvate thereof~~.

5. The compound according to claim 1, wherein the partial structural formula:



is a group represented by the following formula



,

or a pharmaceutically acceptable salt thereof~~, or a solvate thereof~~.

6. The compound according to any one of claims 1 to 5, wherein both $R^4$ and $R^5$ are hydrogen atoms, or a pharmaceutically acceptable salt thereof~~, or a solvate thereof~~.

7. The compound according to any one of claims 1 to 5, wherein $R^3$ is a hydrogen atom, or a pharmaceutically acceptable salt

thereof~~, or a solvate thereof~~.

8. The compound according to any one of claims 1 to 5, wherein $R^1$ is a hydrogen atom, or a pharmaceutically acceptable salt thereof~~, or a solvate thereof~~.

9. The compound according to any one of claims 1 to 5, wherein $R^2$ is

(1) a $C_{1-10}$ alkyl group,

(2) a $C_{6-14}$ aryl group optionally substituted by the same or different 1 to 5 substituents selected from the above-mentioned group B,

(3) a $C_{6-14}$ aryl-$C_{1-6}$ alkyl group (wherein $C_{6-14}$ aryl is optionally substituted by the same or different 1 to 5 substituents selected from the above-mentioned group B), or

(4) a $C_{3-8}$ cycloalkyl-$C_{1-6}$ alkyl group (wherein $C_{3-8}$ cycloalkyl is optionally substituted by the same or different 1 to 5 substituents selected from the above-mentioned group B), or a pharmaceutically acceptable salt thereof~~, or a solvate thereof~~.

10. The compound according to claim 2, wherein both $R^4$ and $R^5$ are hydrogen atoms, or a pharmaceutically acceptable salt thereof~~, or a solvate thereof~~.

11. The compound according to claim 10, wherein $R^3$ is a hydrogen atom, or a pharmaceutically acceptable salt thereof~~, or a solvate thereof~~.

12. The compound according to claim 11, wherein $R^1$ is a hydrogen atom, or a pharmaceutically acceptable salt thereof~~, or a solvate thereof~~.


13. The compound according to claim 12, wherein $R^2$ is

(1) a $C_{1-10}$ alkyl group, or

(2) a $C_{6-14}$ aryl-$C_{1-6}$ alkyl group (wherein $C_{6-14}$ aryl is optionally


substituted by the same or different 1 to 5 substituents selected from the above-mentioned group B),
or a pharmaceutically acceptable salt thereof~~, or a solvate thereof~~.

14. A compound represented by the following formula [I-1] or a pharmaceutically acceptable salt thereof~~, or a solvate thereof~~:




[I-1]

wherein the partial structural formula:



is a group represented by any of the following formulas:



;


$R^{11}$ is

(1) a hydrogen atom,
(2) a $C_{1-6}$ alkyl group,
(3) a phenyl group,
(4) a $C_{3-8}$ cycloalkyl group,
(5) a phenyl-$C_{1-6}$ alkyl group, or
(6) a $C_{3-8}$ cycloalkyl-$C_{1-6}$ alkyl group;




or a pharmaceutically acceptable salt thereof~~, or a solvate thereof~~.

16. A compound represented by the following formula:




or a pharmaceutically acceptable salt thereof~~, or a solvate thereof~~.

17. A compound represented by the following formula:




or a pharmaceutically acceptable salt thereof~~, or a solvate thereof~~.

18. A compound represented by the following formula:




or a pharmaceutically acceptable salt thereof~~, or a solvate thereof~~.

19. A compound represented by the following formula:




or a pharmaceutically acceptable salt thereof~~, or a solvate thereof~~.

20. A compound represented by the following formula:




or a pharmaceutically acceptable salt thereof~~, or a solvate thereof~~.

21. A compound represented by the following formula:




or a pharmaceutically acceptable salt thereof~~, or a solvate thereof~~.

22. A compound represented by the following formula:




or a pharmaceutically acceptable salt thereof~~, or a solvate thereof~~.

23. A compound represented by the following formula:




or a pharmaceutically acceptable salt thereof~~, or a solvate thereof~~.

24. A compound represented by the following formula:



or a pharmaceutically acceptable salt thereof~~, or a solvate thereof~~.

25. A compound represented by the following formula:




or a pharmaceutically acceptable salt thereof~~, or a solvate thereof~~.

26. A pharmaceutical composition comprising the compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, ~~or a solvate thereof,~~ and a pharmaceutically acceptable carrier.

27. A prolyl hydroxylase inhibitor comprising the compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof~~, or a solvate thereof~~.

28. An erythropoietin production-inducing agent comprising the compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof~~, or a solvate thereof~~.

29. A therapeutic agent for anemia comprising the compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof~~, or a solvate thereof~~.

30. A therapeutic agent for renal anemia comprising the compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof~~, or a solvate thereof~~.

31. Use of the compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, ~~or a solvate thereof,~~ for the production of a prolyl hydroxylase inhibitor.

32. Use of the compound according to any one of claims 1 to 25,

or a pharmaceutically acceptable salt thereof, ~~or a solvate thereof,~~ for the production of an erythropoietin production-inducing agent.

33. Use of the compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, ~~or a solvate thereof,~~ for the production of a therapeutic agent for anemia.

34. Use of the compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, ~~or a solvate thereof,~~ for the production of a therapeutic agent for renal anemia.

~~35. A method of inhibiting prolyl hydroxylase, comprising~~ administering an effective amount of the compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, or a solvate thereof to a mammal.

36. A method of inducing erythropoietin production, comprising administering an effective amount of the compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, or a solvate thereof to a mammal.

37. A method of treating anemia, comprising administering an effective amount of the compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, or a solvate thereof to a mammal.

38. A method of treating renal anemia, comprising administering an effective amount of the compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, or a solvate thereof to a mammal.

39. A commercial package comprising the pharmaceutical ~~composition according to claim 26 and a written matter~~

associated therewith, the written matter stating that the pharmaceutical composition can or should be used for the treatment or prophylaxis of a disease selected from anemia and renal anemia.

40. A kit comprising the pharmaceutical composition according to claim 26 and a written matter associated therewith, the written matter stating that the pharmaceutical composition can or should be used for the treatment or prophylaxis of a disease selected from anemia and renal anemia.